Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)

NCT02688985 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

131

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsing Multiple Sclerorsis
Multiple Sclerosis, Primary Progressive

Interventions

DRUG: Ocrelizumab
PROCEDURE: Lumbar Puncture
DRUG: Methyloprednisolone
DRUG: Antihistamine

Sponsor

Genentech, Inc.